Axovant Builds A Case For GSK’s 5-HT6 Castoff In Alzheimer’s
Latest data suggest startup Axovant has a plausible path for its modestly effective RVT-101 toward approval, but the field is still inherently risky and the market is wary nevertheless.
You may also be interested in...
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.
Medicare's Part D plan bidding schedule and uncertainty over the Alzheimer’s drug pipeline is putting plan sponsors in a difficult situation as they contemplate their 2018 bids.